Research shows prostate drug market to double

Tue, 07/20/2010 - 7:34am
Mass High Tech: The Journal of New England Technology

Waltham-based research firm Decision Resources reported today that the launch of nine emerging therapies will help to drive the prostate cancer drug market to more than double to $8.4 billion a year by 2019 in major markets.

In its Pharmacor 2010 report Decision Resources estimated that sales of emerging therapies, most notably Dendreon’s Provenge, will account for 57 percent of the total prostate cancer market in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. In addition to Provenge, market growth will be driven by the uptake of Sanofi-Aventis’s Jevtana, AstraZeneca’s zibotentan, Johnson & Johnson’s abiraterone, Amgen/GlaxoSmithKline/Daiichi Sankyo’s Prolia, Medivation/Astellas Pharma’s MDV-3100, Algeta/Bayer Schering Pharma’s Alpharadin, Bristol-Myers Squibb’s Sprycel and Celgene’s Revlimid.

Provenge gained approval in the U.S. earlier this year.





Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.